Patents by Inventor Ryoji Yanai

Ryoji Yanai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYP450 lipid metabolites reduce inflammation and angiogenesis
    Patent number: 10413518
    Abstract: Methods for reducing angiogenesis, inflammation, and vascular permeability in a subject by administering an epoxymetabolite of Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA), e.g., as listed in Table A, e.g., one or both of 17,18-epoxyeicosatetraenoic acid (EEQ) and 19,20-epoxydocosapentaenoic acid (EDP), e.g., for the treatment of conditions associated with inflammation or excess angiogenesis or neovascularization, including age-related macular degeneration, cancer, stroke, and arthritis.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: September 17, 2019
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Kip M. Connor, Ryoji Yanai
  • CYP450 Lipid Metabolites Reduce Inflammation and Angiogenesis
    Publication number: 20180133187
    Abstract: Methods for reducing angiogenesis, inflammation, and vascular permeability in a subject by administering an epoxymetabolite of Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA), e.g., as listed in Table A, e.g., one or both of 17,18-epoxyeicosatetraenoic acid (EEQ) and 19,20-epoxydocosapentaenoic acid (EDP), e.g., for the treatment of conditions associated with inflammation or excess angiogenesis or neovascularization, including age-related macular degeneration, cancer, stroke, and arthritis.
    Type: Application
    Filed: August 23, 2017
    Publication date: May 17, 2018
    Inventors: Kip M. Connor, Ryoji Yanai
  • CYP450 lipid metabolites reduce inflammation and angiogenesis
    Patent number: 9770426
    Abstract: Methods for reducing angiogenesis, inflammation, and vascular permeability in a subject by administering an epoxymetabolite of Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA), e.g., as listed in Table A, e.g., one or both of 17,18-epoxyeicosatetraenoic acid (EEQ) and 19,20-epoxydocosapentaenoic acid (EDP), e.g., for the treatment of conditions associated with inflammation or excess angiogenesis or neovascularization, including age-related macular degeneration, cancer, stroke, and arthritis.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: September 26, 2017
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Kip M. Connor, Ryoji Yanai
  • CYP450 Lipid Metabolites Reduce Inflammation and Angiogenesis
    Publication number: 20150335603
    Abstract: Methods for reducing angiogenesis, inflammation, and vascular permeability in a subject by administering an epoxymetabolite of Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA), e.g., as listed in Table A, e.g., one or both of 17,18-epoxyeicosatetraenoic acid (EEQ) and 19,20-epoxydocosapentaenoic acid (EDP), e.g., for the treatment of conditions associated with inflammation or excess angiogenesis or neovascularization, including age-related macular degeneration, cancer, stroke, and arthritis.
    Type: Application
    Filed: January 9, 2014
    Publication date: November 26, 2015
    Inventors: Kip M. Connor, Ryoji Yanai